The Enduring Legacy of David Mitchell: Charting the Future of Drug Pricing Reform A decade ago, the conversation around prescription drug pricing felt…stuck. Outrage simmered, but lacked direction. The story of David Mitchell, who recently passed away, wasn’t just about fighting for his own life against multiple myeloma; it was about igniting a movement. His … Read more
Argenx CEO Transition: A Harbinger of Change in Biotech Leadership? The recent announcement of Tim Van Hauwermeiren’s planned departure as CEO of Argenx, coupled with Karen Massey’s appointment as his successor, isn’t just a company-specific event. It’s a potential bellwether for a broader trend: a shift in leadership styles and priorities within the rapidly evolving … Read more
The 10th Filipino Faces of Biotechnology (FoB) Awards were recently presented by the Department of Agriculture Biotechnology Program Office (DA Biotech Program), recognizing individuals who have advanced biotechnology in the Philippines. Recognizing the People Behind the Science The FoB Awards, now in their tenth year, honor scientists, civil servants, farmers, communicators, and student leaders. Judging … Read more
The Price of Secrecy: How Drug Pricing Obscurity Could Shape Healthcare’s Future The recent decision by the Trump administration to delay the public disclosure of net drug prices – the actual amount paid after rebates – isn’t a standalone event. It’s a symptom of a deeper struggle for transparency in the U.S. healthcare system, and … Read more
The Pill Revolution: How Oral Weight Loss Drugs Are Reshaping the Obesity Treatment Landscape For years, the fight against obesity has largely relied on lifestyle changes and injectable medications. Now, a new era is dawning with the FDA’s recent approval of oral Wegovy, Novo Nordisk’s pill form of the blockbuster weight loss drug. This isn’t … Read more
Unlocking New Hope for Cirrhosis: How Epigenetics and Targeted Therapies Could Rewrite the Future of Liver Disease Liver cirrhosis, a condition affecting over a million people globally and contributing to roughly 2.4% of all deaths, has long been a medical challenge. While current treatments focus on managing symptoms, a groundbreaking study from researchers at Miguel … Read more
The Future of Sleep Science: AI, Data, and Personalized Rest For decades, understanding sleep has been a complex puzzle. Traditionally, sleep staging – identifying whether someone is in light sleep, deep sleep, REM, or awake – relied on painstaking manual analysis by trained professionals. But a revolution is underway, driven by artificial intelligence, massive datasets, … Read more
The Rise of Patient‑Specific Cellular Therapies Recent data from Kyverna Therapeutics showed that its personalized CAR‑T platform not only hit the primary endpoint in a pivotal trial for stiff‑person syndrome, but also delivered measurable improvements in walking ability. This is a clear signal that next‑generation cell therapies are moving beyond oncology into rare autoimmune disorders. … Read more
The Obesity Drug Race Heats Up: Beyond Wegovy and Zepbound The weight-loss drug market is no longer a two-horse race. While Novo Nordisk and Eli Lilly currently dominate headlines – and market share – a surge of smaller players and Big Pharma giants are vying for a piece of what analysts predict will be a … Read more
Retatrutide Sets a New Bar for Obesity Therapy Eli Lilly’s next‑generation obesity drug, retatrutide, just delivered the most dramatic weight‑loss results ever recorded in a late‑stage trial. Patients on the highest dose shed an average 23.7 % of body weight after 68 weeks, and a best‑case analysis shows a staggering 28.7 % loss. The same study also reported a … Read more